Spero Therapeutics, Inc. financial data

Symbol
SPRO on Nasdaq
Location
675 Massachusetts Avenue, 14 Th Floor, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 275 % -9.06%
Debt-to-equity 119 % +44.9%
Return On Assets -57.6 % -2691%
Operating Margin -115 % -11033%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.3M shares +3.34%
Common Stock, Shares, Outstanding 56.3M shares +3.68%
Entity Public Float 69.5M USD -8.55%
Common Stock, Value, Issued 56K USD +3.7%
Weighted Average Number of Shares Outstanding, Basic 56.3M shares +3.98%
Weighted Average Number of Shares Outstanding, Diluted 56.3M shares +3.98%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 40.5M USD -61.9%
Revenue from Contract with Customer, Excluding Assessed Tax 64K USD -88.2%
Research and Development Expense 61.7M USD -27%
General and Administrative Expense 23.9M USD +3.69%
Operating Income (Loss) -46.8M USD -4141%
Nonoperating Income (Expense) 3.27M USD -30.6%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -43.8M USD -1343%
Earnings Per Share, Basic 0 USD/shares -1088%
Earnings Per Share, Diluted 0 USD/shares -1088%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 48.6M USD -36.3%
Assets, Current 52.3M USD -60.2%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 1.69M USD -49.9%
Other Assets, Noncurrent 153K USD 0%
Assets 54.2M USD -59.9%
Accounts Payable, Current 1.4M USD -77.1%
Employee-related Liabilities, Current 5.64M USD +72.1%
Liabilities, Current 13.6M USD -72.2%
Operating Lease, Liability, Noncurrent 1.45M USD -49.6%
Liabilities 27.7M USD -60.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -483M USD -9.99%
Stockholders' Equity Attributable to Parent 26.5M USD -59.6%
Liabilities and Equity 54.2M USD -59.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4M USD -167%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 56.3M shares +3.68%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4M USD -167%
Deferred Tax Assets, Valuation Allowance 122M USD +13.3%
Deferred Tax Assets, Gross 122M USD +13.3%
Operating Lease, Liability 4.3M USD -22.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 22.8M USD +91.2%
Lessee, Operating Lease, Liability, to be Paid 4.86M USD -26.1%
Property, Plant and Equipment, Gross 3.62M USD 0%
Operating Lease, Liability, Current 1.9M USD +9.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.96M USD +13.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.75M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 561K USD -45.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.16M USD -33.8%
Deferred Tax Assets, Operating Loss Carryforwards 42.3M USD +65%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.96M USD 0%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%